Who is sponsoring NCT01002872?

NCT01002872 is sponsored by Endeavor Health.

What condition does NCT01002872 study?

NCT01002872 studies Metabolic Bone Disease.

What drugs are being tested in NCT01002872?

Interventions: Lanthanum Carbonate (Fosrenol), placebo.

What is the status of NCT01002872?

NCT01002872 is currently COMPLETED.

Last reviewed 2023-09-19 · How we verify

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease

NCT01002872 NA COMPLETED Results posted

The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD). Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortality.

Details

Lead sponsor	Endeavor Health
Phase	NA
Status	COMPLETED
Enrolment	19
Start date	2009-10
Completion	2012-12

Conditions

Metabolic Bone Disease

Interventions

Lanthanum Carbonate (Fosrenol)
placebo

Primary outcomes

Fibroblast Growth Factor (FGF) 23 Mean Change From Baseline — Baseline, 60 days
Mean change from baseline of FGF23 in subjects treated with Lanthanum Carbonate verse placebo at 60 days

Countries

United States